Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Safety and Feasibility of the CorVad Percutaneous Ventricular Assist System in Refractory Right Heart Failure

NCT: NCT07704424 · RECRUITING

NCT IDNCT07704424
StatusRECRUITING
Start Date2026-06-02
Completion2027-02-28
SponsorShenzhen Core Medical Technology CO.,LTD. (INDUSTRY)
First posted
Last updated

Brief Summary

The goal of this clinical trial is to evaluate the safety and feasibility of the CorVad Percutaneous Ventricular Assist System (Device model: CorVad RS) in patients with right heart failure who continue to experience hemodynamic instability despite best medical therapy.

Frequently Asked Questions

What is Safety and Feasibility of the CorVad Percutaneous Ventricular Assist System in Refractory Right Heart Failure?

Safety and Feasibility of the CorVad Percutaneous Ventricular Assist System in Refractory Right Heart Failure is a clinical trial registered under NCT07704424. Current status: RECRUITING.

What is the status of NCT07704424?

The current status of NCT07704424 (Safety and Feasibility of the CorVad Percutaneous Ventricular Assist System in Refractory Right Heart Failure) is: RECRUITING.

When did Safety and Feasibility of the CorVad Percutaneous Ventricular Assist System in Refractory Right Heart Failure start?

Safety and Feasibility of the CorVad Percutaneous Ventricular Assist System in Refractory Right Heart Failure started on 2026-06-02.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑